Chesapeake Capital Corp IL Invests $442,000 in BioNTech SE (NASDAQ:BNTX)

Chesapeake Capital Corp IL acquired a new position in BioNTech SE (NASDAQ:BNTX) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 3,739 shares of the company’s stock, valued at approximately $442,000.

A number of other large investors also recently modified their holdings of BNTX. Candriam S.C.A. raised its holdings in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after buying an additional 341,311 shares during the period. New York State Common Retirement Fund raised its holdings in shares of BioNTech by 457.9% during the 3rd quarter. New York State Common Retirement Fund now owns 218,067 shares of the company’s stock valued at $25,900,000 after buying an additional 178,981 shares during the period. abrdn plc raised its holdings in shares of BioNTech by 334.4% during the 3rd quarter. abrdn plc now owns 225,992 shares of the company’s stock valued at $26,841,000 after buying an additional 173,969 shares during the period. Finally, Lodestone Wealth Management LLC purchased a new stake in shares of BioNTech during the 3rd quarter valued at about $8,373,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Trading Down 3.7 %

NASDAQ:BNTX opened at $99.72 on Monday. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The firm has a market capitalization of $23.91 billion, a P/E ratio of -47.49 and a beta of 0.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The business has a 50 day simple moving average of $113.54 and a 200 day simple moving average of $97.29.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the previous year, the firm posted $0.73 EPS. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. Equities research analysts predict that BioNTech SE will post -3.68 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BNTX shares. UBS Group raised their target price on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a report on Wednesday, September 18th. Bank of America raised their target price on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. HSBC raised their target price on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $137.54.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.